Daniel Fuster
banner
danfuster.bsky.social
Daniel Fuster
@danfuster.bsky.social
Nephrologist and physician-scientist at Inselspital Bern, Switzerland. Kidney stone and rare kidney disease enthusiast. Passion for climbing, skiing and mountaineering.
Thank you Swiss National Science Foundation !! We just received 3.42 Mio CHF funding for our EMPASTONE trial. Looking forward to working with colleagues in Switzerland, Germany, France, Italy and the UK.
clinicaltrials.gov/study/NCT066...
ClinicalTrials.gov
clinicaltrials.gov
June 17, 2025 at 1:28 PM
Reposted by Daniel Fuster
Our new webinar in german language:

SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz)

WATCH NOW:

youtu.be/i_YTcIQ4YQk?...

@danfuster.bsky.social
@gunnarheine.bsky.social
@marcussaemann.bsky.social
SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz)
YouTube video by MARKUS at HOMe
youtu.be
April 11, 2025 at 5:19 PM
Just out in Nature Communications…..a mystery solved. It’s all about lipids in the regulation of intracellular NHEs. Thank you David for this great collaboration.
rdcu.be/efxE2
PIP2-mediated oligomerization of the endosomal sodium/proton exchanger NHE9
Nature Communications - Na+ /H+ exchangers regulate intracellular pH, sodium levels, and cell volume. Cryo-EM structures reveal lipid coordination at the dimer interfaces of NhaA with cardiolipin...
rdcu.be
March 28, 2025 at 6:55 PM
Reposted by Daniel Fuster
So @danfuster.bsky.social and colleagues seem to find HCTZ doesn’t work for anything!

In a post hoc analysis of NOSTONE (where CT scans were done in all & repurposed for calculating bone density) HCTZ doesn’t increase it vs placebo

journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social
March 19, 2025 at 11:22 AM
Reposted by Daniel Fuster
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: A Post Hoc Analysis of the NOSTONE Trial by Drs. Christe, @danfuster.bsky.social et al.

journals.lww.com/cjasn/abstra...

HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years!
March 12, 2025 at 6:10 PM
Reposted by Daniel Fuster
Happy to share that our research letter has been accepted in @ndt-era.bsky.social. Here we showed that impaired renal acid excretion is strongly associated with CaOx stone presence in the Swiss Kidney Stone Cohort: bit.ly/41rKodu. Many thanks to all co-authors in Switzerland for their support.
Acid excretion is impaired in calcium oxalate stone formers
Pedro H Imenez Silva, Nasser A Dhayat, Daniel G Fuster, Harald Seeger, Alexander Ritter, Thomas Ernandez, Florian Buchkremer, Beat Roth, Olivier Bonny, Isa
bit.ly
March 4, 2025 at 4:03 PM
HCTZ not better than placebo for the prevention of BMD loss among individuals with calcium kidney stones

journals.lww.com/cjasn/abstra...
Hydrochlorothiazide and Bone Mineral Density in Patients... : Clinical Journal of the American Society of Nephrology
three-year period. Methods: This post-hoc analysis was conducted on data from the NOSTONE trial, a multicenter, randomized, controlled study. A total of 416 adults with recurrent calcium stones par...
journals.lww.com
March 10, 2025 at 5:41 PM
Excited to share the results of our SWEESTONE trial 🔥🔥🔥@NatureMedicine
Wonderful collaboration with colleagues @unibern @inselgruppe and DCR Bern.
www.nature.com/articles/s41...
Empagliflozin substantially reduced urinary supersaturations in non-diabetic patients with kidney stones.
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial - Nature Medicine
As part of the SWEETSTONE trial, the authors report the ability of the sodium-glucose cotransporter 2 inhibitor empagliflozin to reduce the likelihood of kidney stone formation in individuals without ...
www.nature.com
January 2, 2025 at 10:36 AM
Chlorthalidone is not better than hydrochlorothiazide in kidney outcome prevention in a secondary analysis of the large DCP study. Very important results.
jamanetwork.com/journals/jam...
Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes
This secondary analysis of a randomized clinical trial examines whether chlorthalidone is superior to hydrochlorothiazide in preventing kidney outcomes in patients with hypertension.
jamanetwork.com
December 14, 2024 at 2:28 PM
Reposted by Daniel Fuster
… and you might even dream (or fool yourself?) about achieving lower sodium intake in your patients, but the most likely explanation for the negative result of #NOSTONE, is just that: Thiazides do not work very well in preventing recurrent kidney stones. 2/2
December 7, 2024 at 10:02 PM
Reposted by Daniel Fuster
I’m biased (local PI, steering committee), but the quality of #NOSTONE far exceeds most (if not all) data that the critics base their many assumptions and beliefs on.
You can speculate about the additional effects of citrate or a different type or dose of diuretic, … 1/2
Terrible, terrible study. They had such an opportunity to answer the question once and for all and failed.
December 7, 2024 at 10:02 PM
Acidosis and CKD journals.lww.com/cjasn/citati...
"Whether there will be a definitive, adequately powered trial of this inexpensive, fairly safe intervention in CKD is up to funding
agencies to decide"
Cardiology is doing large outcome trials with colchicine - why can we not do this with alkali ?
journals.lww.com
November 21, 2024 at 8:29 PM